HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Operating Margin
- Operating margin · 12 months: Value 24.03%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 24.03% | Operating income / revenue. Period ending 2026-06-30. $230.65M ÷ $959.90M × 100 ≈ 24.03% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 230.65M USD | Operating Income (Loss) |
| Revenue | 959.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 235.91M USD | Cost of Goods and Services Sold |
| Research and development | 220.87M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $230.65M | $959.90M | $235.91M | $220.87M | (m) | 24.03% |
| 2026-03-31 | $189.51M | $899.11M | $210.86M | $224.44M | (m) | 21.08% |
| 2025-12-31 | $208.47M | $868.45M | $198.34M | $189.59M | (m) | 24.00% |
| 2025-09-30 | $225.64M | $825.94M | $184.21M | $174.33M | (m) | 27.32% |
| 2025-06-30 | $221.86M | $772.53M | $167.33M | $144.75M | (m) | 28.72% |
| 2025-03-31 | $195.04M | $744.85M | $161.32M | $158.18M | (m) | 26.18% |
| 2024-12-31 | $190.83M | $714.73M | $156.81M | $145.82M | (m) | 26.70% |
| 2024-09-30 | $175.29M | $681.88M | $145.56M | $141.47M | (m) | 25.71% |
| 2024-06-30 | $178.09M | $656.11M | $135.08M | $133.58M | (m) | 27.14% |
| 2024-03-31 | $203.64M | $617.51M | $127.94M | $84.96M | (m) | 32.98% |
| 2023-12-31 | $192.03M | $582.02M | $121.24M | $76.06M | (m) | 32.99% |
| 2023-09-30 | $199.45M | $541.92M | $104.97M | $55.85M | (m) | 36.80% |
| 2023-06-30 | $146.84M | $498.86M | $95.63M | $78.90M | (m) | 29.44% |
| 2023-03-31 | $133.05M | $471.67M | $89.55M | $76.60M | (m) | 28.21% |
| 2022-12-31 | $120.19M | $437.86M | $83.48M | $70.89M | (m) | 27.45% |
| 2022-09-30 | $101.20M | $400.76M | $74.41M | $68.25M | (m) | 25.25% |
| 2022-06-30 | $110.36M | $364.29M | $66.06M | $39.44M | (m) | 30.29% |
| 2022-03-31 | $100.55M | $331.08M | $59.83M | $33.27M | (m) | 30.37% |
| 2021-12-31 | $87.53M | $305.44M | $55.52M | $30.37M | (m) | 28.66% |
| 2021-09-30 | $66.66M | $270.51M | $47.62M | $30.54M | (m) | 24.64% |
| 2021-06-30 | $55.98M | $235.39M | $40.91M | $23.02M | (m) | 23.78% |
| 2021-03-31 | $41.13M | $199.58M | $34.67M | $20.70M | (m) | 20.61% |
| 2020-12-31 | $16.99M | $159.74M | $27.74M | $19.45M | (m) | 10.63% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-145.90M | $6.00M | $1.58M | $69.59M | (m) | -2433.76% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |